{"id":4816,"date":"2025-08-12T10:24:37","date_gmt":"2025-08-12T10:24:37","guid":{"rendered":"https:\/\/www.dsru.org\/?post_type=abstract&#038;p=4816"},"modified":"2026-07-23T15:05:53","modified_gmt":"2026-07-23T15:05:53","slug":"abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study","status":"publish","type":"abstract","link":"https:\/\/www.dsru.org\/abstract\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\/","title":{"rendered":"Abstract 269: Assessment of Start Dose in Patients Prescribed Rivaroxaban for Atrial Fibrillation with Chronic Kidney Disease-Results from the ROSE Study"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Miranda Davies 1, 2, Alison Evans 1,2, Flavien Coukan 1, 2, Lesley Wise1, Saad Shakir 1,2<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Affiliations: 1 Drug Safety Research Unit, 2 University of Portsmouth<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Background<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Rivaroxaban is used to treat patients with non-valvular AF for the prevention of stroke and systemic embolism. This requires a fixed daily dose (20mg) with dosage reduction only recommended in patients with a reduced creatinine clearance (15-49 ml\/min), a range encompassed within chronic kidney disease (CKD) stage 3-4 (eGFR 15-59) although CKD 3a (eGFR 45-59) is largely outside this range. Rivaroxaban is not recommended in patients with severe renal impairment (creatinine clearance &lt; 15 ml\/min).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Objectives<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">To assess starting dose amongst patients with chronic kidney disease stage 3-4 or 5.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Methods<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The ROSE study was a specialist cohort event monitoring study of patients prescribed rivaroxaban. Specialists provided information via detailed questionnaires at baseline (and \u2265 12weeks). Baseline characteristics included starting dose and presence of either CKD stage 3-4 (eGFR 15-59) or CKD stage 5 (eGFR &lt; 15). Starting dose was examined amongst patients with CKD stage 3-4 and 5 to assess how many patients had a reduced starting dose of less than 20mg od.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Results<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The cohort consisted of 965 patients with AF: 75 patients with history of either stage 3-4 CKD (n=73, 7.6%) or stage 5 CKD (n=2, 0.2%). Of the patients with CKD stage 3-4, 36 (49.3 %) were started on &lt;20 mg daily (15mg od [n=35]; 10mg od [n=1]). 35 patients (48.0 %) were started on \u2265 20mg (20mg od [n=34]; 30mg od [n=1]). Starting dose was missing for two patients (2.7%). Neither patient with CKD stage 5 had a dose reduction.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusion<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Our results suggest that amongst patients with CKD stage 3-4, approximately half were started on the recommended reduced dose of &lt; 20mg od. Not all patients with CKD stage 3-4 would be recommended a dose reduction as per the product label. A UK audit suggests that approximately 20% of patients in the UK with CKD 3 are 3b rather than 3a although the frequency may be higher in a hospital cohort.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"categories":[45],"tags":[],"class_list":["post-4816","abstract","type-abstract","status-publish","hentry","category-isop-18th-annual-meeting-geneva-november-2018"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abstract 269: Rivaroxaban Dosing in CKD &amp; Atrial Fib<\/title>\n<meta name=\"description\" content=\"DSRU&#039;s ROSE study abstract on rivaroxaban starting dose in atrial fibrillation patients with chronic kidney disease stage 3-4 and 5.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.dsru.org\/abstract\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abstract 269: Rivaroxaban Dosing in CKD &amp; Atrial Fib\" \/>\n<meta property=\"og:description\" content=\"DSRU&#039;s ROSE study abstract on rivaroxaban starting dose in atrial fibrillation patients with chronic kidney disease stage 3-4 and 5.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.dsru.org\/abstract\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\/\" \/>\n<meta property=\"og:site_name\" content=\"DSRU\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DrugSafetyResearchUnit\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T15:05:53+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@DSRUDrugSafety\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n\t<meta name=\"twitter:label2\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data2\" content=\"ashleigh barton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/abstract\\\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\\\/\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/abstract\\\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\\\/\",\"name\":\"Abstract 269: Rivaroxaban Dosing in CKD & Atrial Fib\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#website\"},\"datePublished\":\"2025-08-12T10:24:37+00:00\",\"dateModified\":\"2026-07-23T15:05:53+00:00\",\"description\":\"DSRU's ROSE study abstract on rivaroxaban starting dose in atrial fibrillation patients with chronic kidney disease stage 3-4 and 5.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/abstract\\\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.dsru.org\\\/abstract\\\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/abstract\\\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.dsru.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abstract 269: Assessment of Start Dose in Patients Prescribed Rivaroxaban for Atrial Fibrillation with Chronic Kidney Disease-Results from the ROSE Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#website\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/\",\"name\":\"DSRU\",\"description\":\"The UK\u2019s leading pharmacovigilance and pharmacoepidemiology unit.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#organization\"},\"alternateName\":\"Drug Safety Research Unit\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.dsru.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#organization\",\"name\":\"DSRU\",\"alternateName\":\"Drug Safety Research Unit\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/cropped-DSRU_Branding.png\",\"contentUrl\":\"https:\\\/\\\/www.dsru.org\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/cropped-DSRU_Branding.png\",\"width\":250,\"height\":115,\"caption\":\"DSRU\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/DrugSafetyResearchUnit\",\"https:\\\/\\\/x.com\\\/DSRUDrugSafety\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/drug-safety-research-unit\\\/\",\"https:\\\/\\\/www.instagram.com\\\/drugsafetyresearchunit\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abstract 269: Rivaroxaban Dosing in CKD & Atrial Fib","description":"DSRU's ROSE study abstract on rivaroxaban starting dose in atrial fibrillation patients with chronic kidney disease stage 3-4 and 5.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.dsru.org\/abstract\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\/","og_locale":"en_GB","og_type":"article","og_title":"Abstract 269: Rivaroxaban Dosing in CKD & Atrial Fib","og_description":"DSRU's ROSE study abstract on rivaroxaban starting dose in atrial fibrillation patients with chronic kidney disease stage 3-4 and 5.","og_url":"https:\/\/www.dsru.org\/abstract\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\/","og_site_name":"DSRU","article_publisher":"https:\/\/www.facebook.com\/DrugSafetyResearchUnit","article_modified_time":"2026-07-23T15:05:53+00:00","twitter_card":"summary_large_image","twitter_site":"@DSRUDrugSafety","twitter_misc":{"Estimated reading time":"1 minute","Written by":"ashleigh barton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.dsru.org\/abstract\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\/","url":"https:\/\/www.dsru.org\/abstract\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\/","name":"Abstract 269: Rivaroxaban Dosing in CKD & Atrial Fib","isPartOf":{"@id":"https:\/\/www.dsru.org\/#website"},"datePublished":"2025-08-12T10:24:37+00:00","dateModified":"2026-07-23T15:05:53+00:00","description":"DSRU's ROSE study abstract on rivaroxaban starting dose in atrial fibrillation patients with chronic kidney disease stage 3-4 and 5.","breadcrumb":{"@id":"https:\/\/www.dsru.org\/abstract\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.dsru.org\/abstract\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.dsru.org\/abstract\/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.dsru.org\/"},{"@type":"ListItem","position":2,"name":"Abstract 269: Assessment of Start Dose in Patients Prescribed Rivaroxaban for Atrial Fibrillation with Chronic Kidney Disease-Results from the ROSE Study"}]},{"@type":"WebSite","@id":"https:\/\/www.dsru.org\/#website","url":"https:\/\/www.dsru.org\/","name":"DSRU","description":"The UK\u2019s leading pharmacovigilance and pharmacoepidemiology unit.","publisher":{"@id":"https:\/\/www.dsru.org\/#organization"},"alternateName":"Drug Safety Research Unit","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.dsru.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.dsru.org\/#organization","name":"DSRU","alternateName":"Drug Safety Research Unit","url":"https:\/\/www.dsru.org\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.dsru.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.dsru.org\/wp-content\/uploads\/2022\/01\/cropped-DSRU_Branding.png","contentUrl":"https:\/\/www.dsru.org\/wp-content\/uploads\/2022\/01\/cropped-DSRU_Branding.png","width":250,"height":115,"caption":"DSRU"},"image":{"@id":"https:\/\/www.dsru.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/DrugSafetyResearchUnit","https:\/\/x.com\/DSRUDrugSafety","https:\/\/www.linkedin.com\/company\/drug-safety-research-unit\/","https:\/\/www.instagram.com\/drugsafetyresearchunit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/abstract\/4816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/abstract"}],"about":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/types\/abstract"}],"wp:attachment":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/media?parent=4816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/categories?post=4816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/tags?post=4816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}